VANCOUVER, April 19, 2017 /CNW/ - INVICTUS MD
STRATEGIES CORP. ("Invictus MD" or the "Company")
(TSXV: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that
AB Laboratories Inc. ("AB Labs"), a Licensed Producer under the
Access to Cannabis for Medical Purposes Regulations ("ACMPR"), will
provide their unique products in Canopy Growth Corporation's
(TSX:WEED) ("Canopy Growth") curated CraftGrow line on Tweed Main
Street's online store, that brings high quality cannabis grown by a
diverse set of producers. People want variety, they want different
choices, and Tweed Main Street is an opportunity in the legal
market where patients can see what is available through the
convenience of an online store.
"AB Labs has received a number of direct inquiries from
patients, which underscores the continuously growing demand. As a
newer licensed producer with a market capitalization less than our
peers, we are able to utilize Canopy Growth's Tweed Main
Street, giving us immediate access to the largest customer base in
the rapidly expanding medical cannabis market." said Dan Kriznic,
Chairman and CEO of Invictus MD. "Our collaboration with
Canopy Growth demonstrates our commitment to making the sector
strong and helping to expose medical cannabis patients visiting
Tweed Main Street, to another high quality, unique brand."
With Canada on the global stage
as it moves closer to making history by being the first G-7 nation
to legalize and regulate access to cannabis for the
recreational market and the expected demand that will result,
Invictus MD will continue to focus on building out AB Labs and AB
Ventures Inc.'s ("AB Ventures") production capacity in Ontario and successfully acquiring Acreage
Pharms Ltd.'s ("Acreage Pharms") production facility in
Alberta. After the successful development and acquisition of
these facilities, Invictus MD anticipates that it will have the
capacity to supply more than 50,000 kg of cannabis by 2020. This
creates an attractive value proposition in the burgeoning cannabis
market.
AB Labs, which maintains a 16,000 square foot facility located
near Hamilton, Ontario, has
successfully conducted test crops and is currently operating at
half capacity, with full production capacity scheduled by the end
of May 2017. AB Ventures Inc.'s ("AB Ventures"), a company
formed to develop a second licensed expansion facility through it's
common ownership with AB Labs, is expected to close a 100-acre
acquisition on May 1, 2017, and if
licensed under the ACMPR, construction of production facilities
totaling 250,000 square feet will begin and be used for future
cannabis cultivation. With licensing in place as expected,
production at AB Ventures is anticipated to start as early as
December 2017.
Considering the magnitude of AB Ventures' land acquisition and
future production facilities, and assuming AB Ventures obtains a
license to produce the quantity forecasted, Invictus MD anticipates
the combined production capacity of both AB Labs and AB Ventures to
exceed 25,000 kilograms in 2020.
About Invictus MD Strategies Corp.
Invictus MD Strategies Corp. is focused on three main verticals
within the burgeoning Canadian cannabis sector: Licensed Producers
under the ACMPR including an investment in a fully licensed
facility, AB Laboratories Inc. as well as the option to now acquire
100% of Acreage Pharms Ltd.; Fertilizer and Nutrients through
Future Harvest Development Ltd.; and Cannabis Data and Delivery,
with its wholly owned subsidiary Poda Technologies Ltd.
For more information, please visit www.invictus-md.com.
On Behalf of the Board,
Dan Kriznic
Chairman & CEO
Larry Heinzlmeir
Vice President, Marketing & Communications
604-537-8676
Cautionary Note Regarding Forward-Looking Statements: This
release includes certain statements and information that may
constitute forward-looking information within the meaning of
applicable Canadian securities laws or forward-looking statements
within the meaning of the United States Private Securities
Litigation Reform Act of 1995. All statements in this news release,
other than statements of historical facts, including statements
regarding future estimates, plans, objectives, assumptions or
expectations of future performance, including the proposed exercise
of the Option and successful acquisition of Acreage Pharms, the
potential production capacity of the AB Labs, AB Ventures and
Acreage Pharms' production facilities, the granting of regulatory
approval and anticipated timing of AB Labs reaching full production
capacity, the granting of a license under the ACMPR to AB Ventures,
the success and timing of AB Ventures acquisition of 100-acre of
land, the timing of the start of production at AB Ventures'
facility are forward-looking statements and contain forward-looking
information. Generally, forward-looking statements and information
can be identified by the use of forward-looking terminology such as
"intends" or "anticipates", or variations of such words and phrases
or statements that certain actions, events or results "may",
"could", "should", "would" or "occur". Forward-looking statements
are based on certain material assumptions and analysis made by the
Company and the opinions and estimates of management as of the date
of this press release, including the assumptions that the Company
will successfully acquire Acreage Pharms and that the Company will
obtain stock exchange and all other applicable regulatory approvals
of the proposed Option, AB Labs, AB Ventures and Acreage Pharms
will receive regulatory approval to produce medical cannabis at
their production facilities' full capacity, AB Ventures will be
granted a license under the ACMPR, AB Ventures is able to
successfully negotiate and close the 100-acre land acquisition, AB
Ventures is able to successfully build a production facility. These
forward-looking statements are subject to known and unknown risks,
uncertainties and other factors that may cause the actual results,
level of activity, performance or achievements of the Company to be
materially different from those expressed or implied by such
forward-looking statements or forward-looking information.
Important factors that may cause actual results to vary, include,
without limitation, the risk that the proposed exercise of the
Option may not occur as planned;, AB Labs, AB Ventures and Acreage
Pharms will not receive regulatory approval to produce medical
cannabis at their production facilities or reach full production
capacity, AB Ventures will not be granted a license under the
ACMPR, AB Ventures is not able to successfully negotiate and close
the 100-acre land acquisition, AB Ventures is not able to
successfully build a production facility;. Although management of
the Company has attempted to identify important factors that could
cause actual results to differ materially from those contained in
forward-looking statements or forward-looking information, there
may be other factors that cause results not to be as anticipated,
estimated or intended. There can be no assurance that such
statements will prove to be accurate, as actual results and future
events could differ materially from those anticipated in such
statements. Accordingly, readers should not place undue reliance on
forward-looking statements and forward-looking information. Readers
are cautioned that reliance on such information may not be
appropriate for other purposes. The Company does not undertake to
update any forward-looking statement, forward-looking information
or financial out-look that are incorporated by reference herein,
except in accordance with applicable securities laws. We seek safe
harbor.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE Invictus MD Strategies